{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:44:31Z","timestamp":1777041871028,"version":"3.51.4"},"reference-count":42,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\u00a0and Clinical Significance: Chromothripsis represents a catastrophic genomic event in plasma cell myeloma (PCM) associated with poor prognosis. We report a case of newly diagnosed PCM with complex cytogenetic abnormalities indicative of genomic instability. Case Presentation: A 67-year-old man presented with acute dyspnea and was found to have severe acute kidney injury, anemia, hypercalcemia, and IgG lambda monoclonal gammopathy. Bone marrow biopsy revealed plasma cell infiltration. Comprehensive FISH analysis demonstrated a complex pattern with gain of 1q, monosomy 13, and multiple numeric and structural abnormalities affecting chromosomes 5, 9, and 15, suggestive of a chromothripsis-like pattern. Despite requiring hemodialysis, the patient achieved complete renal recovery and &gt;99% reduction in serum-free light chains after one cycle of CyBorD plus daratumumab, which was continued for four cycles. Follow-up bone marrow evaluation at three months confirmed complete histologic, flow cytometric, and cytogenetic remission, allowing for preparation for autologous stem cell transplantation. Conclusions: This case demonstrates that exceptional clinical responses can be achieved in high-risk disease with contemporary quadruplet regimens. While the long-term durability of such responses in genomically unstable cases remains uncertain, this case highlights the importance of comprehensive cytogenetic characterization to identify and monitor genomic instability in PCM.<\/jats:p>","DOI":"10.3390\/diagnostics16091280","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:29:11Z","timestamp":1777033751000},"page":"1280","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complex Chromothripsis-like Features in Plasma Cell Myeloma: A Case Report and Review of the Literature"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5186-551X","authenticated-orcid":false,"given":"Jaymie","family":"Oentoro","sequence":"first","affiliation":[{"name":"Department of Pathology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8634-2893","authenticated-orcid":false,"given":"Kevin A.","family":"Murgas","sequence":"additional","affiliation":[{"name":"Medical Scientist Training Program, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8765-004X","authenticated-orcid":false,"given":"Jacob","family":"Rocha","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahmeena","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5339-5347","authenticated-orcid":false,"given":"Carlos A.","family":"Tirado","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple Myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Thakral, B., Vijayanarayanan, A., Medeiros, L.J., and Lin, P. (2025). Cytogenetic and Molecular Aberrations at Diagnosis and in Prognosis of Multiple Myeloma, Elsevier.","DOI":"10.1016\/j.semdp.2025.150915"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic Complexity of Multiple Myeloma and Its Clinical Implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","first-page":"1919","article-title":"Characterizing the Mutational Landscape of MM and Its Precursor MGUS","volume":"12","author":"Farswan","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"78234","DOI":"10.18632\/oncotarget.20829","article-title":"Chromosomal Instability and Acquired Drug Resistance in Multiple Myeloma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome Instability in Multiple Myeloma","volume":"34","author":"Neuse","year":"2020","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","article-title":"Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development","volume":"144","author":"Stephens","year":"2011","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.cell.2015.11.054","article-title":"Chromothripsis and Kataegis Induced by Telomere Crisis","volume":"163","author":"Maciejowski","year":"2015","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature14493","article-title":"Chromothripsis from DNA Damage in Micronuclei","volume":"522","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.tcb.2017.08.005","article-title":"Rebuilding Chromosomes after Catastrophe: Emerging Mechanisms of Chromothripsis","volume":"27","author":"Ly","year":"2017","journal-title":"Trends Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gde.2020.02.009","article-title":"Chromothripsis and Telomere Crisis: Engines of Genome Instability","volume":"60","author":"Dewhurst","year":"2020","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","article-title":"Comprehensive Analysis of Chromothripsis in 2,658 Human Cancers Using Whole-Genome Sequencing","volume":"52","author":"Lee","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/s41467-024-49985-5","article-title":"Non-Homologous End Joining Shapes the Genomic Rearrangement Landscape of Chromothripsis from Mitotic Errors","volume":"15","author":"Hu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41576-023-00663-0","article-title":"Scrambling the Genome in Cancer: Causes and Consequences of Complex Chromosome Rearrangements","volume":"25","author":"Krupina","year":"2024","journal-title":"Nat. Rev. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cell.2013.02.023","article-title":"Criteria for Inference of Chromothripsis in Cancer Genomes","volume":"152","author":"Korbel","year":"2013","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.semcdb.2021.02.001","article-title":"Chromothripsis, DNA Repair and Checkpoints Defects","volume":"Volume 123","author":"Simovic","year":"2022","journal-title":"Proceedings of the Seminars in Cell & Developmental Biology"},{"key":"ref_17","first-page":"675","article-title":"Chromothripsis Identifies a Rare and Aggressive Entity among Newly Diagnosed Multiple Myeloma Patients","volume":"118","author":"Magrangeas","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2018.12.005","article-title":"Clinical Impact of Chromothriptic Complex Chromosomal Rearrangements in Newly Diagnosed Multiple Myeloma","volume":"76","author":"Kaur","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic Landscape and Chronological Reconstruction of Driver Events in Multiple Myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcdb.2021.04.014","article-title":"Chromothripsis as a Pathogenic Driver of Multiple Myeloma","volume":"Volume 123","author":"Maura","year":"2022","journal-title":"Proceedings of the Seminars in Cell & Developmental Biology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.ajhg.2021.05.012","article-title":"Optical Genome Mapping Enables Constitutional Chromosomal Aberration Detection","volume":"108","author":"Mantere","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1038\/s41467-021-25469-8","article-title":"Copy Number Signatures Predict Chromothripsis and Clinical Outcomes in Newly Diagnosed Multiple Myeloma","volume":"12","author":"Maclachlan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A High-Risk, Double-Hit, Group of Newly Diagnosed Myeloma Identified by Genomic Analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"ref_26","unstructured":"(2026, April 16). mSMART 4.0: Mayo Stratification for Myeloma and Risk-Adapted Therapy. Available online: https:\/\/www.msmart.org\/mm-treatment-guidelines."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/cncr.34641","article-title":"The Prognostic Role of 1q21 Gain\/Amplification in Newly Diagnosed Multiple Myeloma: The Faster, the Worse","volume":"129","author":"Wang","year":"2023","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","volume":"43","author":"Davies","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","article-title":"The Prognostic Significance of Cytogenetics and Molecular Profiling in Multiple Myeloma","volume":"204","author":"Sawyer","year":"2011","journal-title":"Cancer Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-22-3209","article-title":"Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma","volume":"29","author":"Boyle","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_31","first-page":"2583","article-title":"Monosomy 13 Is Associated with the Transition of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma","volume":"94","author":"Li","year":"1999","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1038\/bcj.2017.83","article-title":"Prognostic Implications of Abnormalities of Chromosome 13 and the Presence of Multiple Cytogenetic High-Risk Abnormalities in Newly Diagnosed Multiple Myeloma","volume":"7","author":"Binder","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-Risk Cytogenetic Factors: A Systematic Review and Meta-Analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood-2018-152","article-title":"Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)","volume":"132","author":"Yimer","year":"2018","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2012.182","article-title":"The Role of Novel Agents on the Reversibility of Renal Impairment in Newly Diagnosed Symptomatic Patients with Multiple Myeloma","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s13730-016-0231-4","article-title":"Successful Treatment of Myeloma Cast Nephropathy Using Bortezomib-Based Chemotherapy plus Selective Plasma Exchange","volume":"5","author":"Kawabe","year":"2016","journal-title":"CEN Case Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.kint.2020.11.010","article-title":"International Kidney and Monoclonal Gammopathy Research Group Management of Acute Kidney Injury in Symptomatic Multiple Myeloma","volume":"99","author":"Bridoux","year":"2021","journal-title":"Kidney Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"108007","DOI":"10.1016\/j.pharmthera.2021.108007","article-title":"Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma","volume":"232","author":"Choi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-Cell-Engaging Bispecific Antibodies in Cancer","volume":"402","author":"Zweegman","year":"2023","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-025-01286-w","article-title":"Guidelines for the Testing and Reporting of Cytogenetic Results for Risk Stratification of Multiple Myeloma: A Report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group","volume":"15","author":"Lu","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_42","unstructured":"Hastings, R.J., Moore, S., and Chia, N. (2024). ISCN 2024: An International System for Human Cytogenomic Nomenclature (2024), Karger Medical and Scientific Publishers."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/9\/1280\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:45:29Z","timestamp":1777034729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/9\/1280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["diagnostics16091280"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16091280","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}